Last reviewed · How we verify
alfuzosin (SL770499)
alfuzosin (SL770499) is a Alpha-1 adrenergic receptor antagonist Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Benign prostatic hyperplasia (BPH).
Alfuzosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow.
Alfuzosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow. Used for Benign prostatic hyperplasia (BPH).
At a glance
| Generic name | alfuzosin (SL770499) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
By blocking alpha-1 adrenergic receptors, alfuzosin reduces the muscle tone in the prostate and bladder neck, allowing for easier urination. This is particularly beneficial for men with benign prostatic hyperplasia (BPH).
Approved indications
- Benign prostatic hyperplasia (BPH)
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
- Orthostatic hypotension
Key clinical trials
- Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology (PHASE3)
- Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction (PHASE3)
- Benign Prostatic Hyperplasia in Taiwan (NA)
- Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology (PHASE3)
- Clinical Trial in Males With BPH (Enlarged Prostate) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alfuzosin (SL770499) CI brief — competitive landscape report
- alfuzosin (SL770499) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about alfuzosin (SL770499)
What is alfuzosin (SL770499)?
How does alfuzosin (SL770499) work?
What is alfuzosin (SL770499) used for?
Who makes alfuzosin (SL770499)?
What drug class is alfuzosin (SL770499) in?
What development phase is alfuzosin (SL770499) in?
What are the side effects of alfuzosin (SL770499)?
What does alfuzosin (SL770499) target?
Related
- Drug class: All Alpha-1 adrenergic receptor antagonist drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Benign prostatic hyperplasia (BPH)
- Compare: alfuzosin (SL770499) vs similar drugs
- Pricing: alfuzosin (SL770499) cost, discount & access